Connect with us

News

What does the future of femtech look like?

Femtech examines if this year’s early trends could one to watch for 2023

Published

on

Femtech futures: Innovation in products

Tech forecasting agency, Ultra Violet Futures has launched a report outlining what it predicts will be the new futures in Femtech for 2023

The femtech industry is set to rise to be a $1.186 trillion global market by 2027. As an emerging sector, it is also poised to expand by adopting new and exciting technology such as techceuticals, virtual clinics or metaverses. The report by Ultraviolet focuses on four key future trends in femtech and what these may look like in 2023. Including Working across the 4 macro trends of Hybrid Health, Enhanced Therapies, Well-th Economy, and Radical Inclusivity 2.0.

So what does this mean for femtech companies looking to enter the market and strength their position?

FemTech World examines the new trends and technologies that are set to shape the industry for 2023

Real artificial worlds

The rise in metauniverses and VR experiences have highlighted a desire to go beyond technology and place ourselves within virtual worlds. This is only set to continue as companies such as Facebook, or Meta as it is called now, move to position themselves within artificial worlds or build their own.

Although so far, the worlds are limited to very basic experiences such as entering stores to purchase products that then appear at your door in real-time. However, there is a growing movement to see how this could be taken beyond the 2D into real touch much the way that sound and vision are already incorporated.

Meta has already begun developing a product for this called ReSkin. This is an open-source touch-sensing ‘skin’ which has created in collaboration with Carnegie Mellon University. It is aimed at helping researchers to advance their AI’s tactile-sensing skills quickly and at scale. It should produce enough data to help advance AI in a wide range of touch-based tasks including object classification, proprioception, and robotic grasping.

What would this mean for femtech companies?

Introducing a softer touch or interactive experience to healthcare could be a game-changer. As we introduce more senses into the virtual experience then it ceases to become a sterile environment. It could help to build a complete experience for the patient where they can feel relaxed, at home in their own surroundings but with full access to a complete health check-up or experts.

But are patients ready for this?

After two years of pandemic Zoom appointments says, well, yes. In a recent study, 78 per cent of consumers said when interacting with people online, they ‘missed the ability to physically touch or interact with them.’ While the metaverse may only be emerging as a potentially viable opportunity for brands, it could be vital that companies assess new alternative methods of reaching their audience – on or offline.

Femtech futures: Innovation in products
Radical inclusivity

This has already started within health and femtech with more companies leading the charge in inclusive language, apps, marketing and healthcare.

There has been a huge gap in the market for products that acknowledge the fluidity of gender and the limits that ‘his or her’ tech devices can have. Companies particularly in the femtech, period care or sextech industries have already introduced gender-neutral language, non-gendered toys or even marketing that is non-gender biased.

Studies show that women make up only a quarter of tech developers in the market which may explain why female tech developers are embracing inclusivity in their companies. A glass ceiling needs to be properly smashed for everyone not just one sector.

By embracing other minority groups within the products, femtech designers are addressing needs that are generally not catered for with mainstream concepts. One example of this is FEWE’s marketing campaign around transmen who experience periods and need menstrual care products. Their slogan instantly sets the tone: ‘female-founded cycle care for every phase, for everybody.’

In addressing this, the gender pain or data gap becomes smaller as we begin to learn more.

New future for women in femtech

The report also noted that femtech companies are more inclined to embrace flexible working patterns which can help women with reaching their life goals.

It acknowledged that women were being overlooked by policymakers when it came to professional or familial support. This meant a ‘mass exodus of women from the workplace’ that has a knock-on effect on the gender pay or data gap. The results mean more men in board rooms than women.

The pandemic has forced creative thinking around schedules and normalcy in our careers but this is slowly moving back to a nine to five in office model post-lockdown. Femtech companies are determined to drive action-orientated change that aims to find a solution.

One great example is Carrot fertility, a female-founded tech that allows employees to request fertility coaching at their jobs. The benefits of fertility coaching are thought to be better stress or anxiety management and also reduced costs. But it can be simple such as flexible working times for mums or hybrid working for pregnant workers. Other innovative solutions could also mean breast milk shipping services for working mothers.

Insight

Online abuse and deepfakes ‘pushing women out of public life’

Published

on

Deepfakes, AI-assisted rape and unwanted advances are pushing women out of public life, a report has found.

Online violence against women in public life is becoming increasingly technologically sophisticated, with perpetrators able to use AI tools to fabricate intimate images of their targets.

Survey responses suggest these attacks are often deliberate and coordinated, aiming to silence women in public life while undermining their professional credibility and personal reputations.

The report, “Tipping point: Online violence impacts, manifestations and redress in the AI age”, was published by UN Women and produced in partnership with City St George’s, University of London, and TheNerve, a digital forensics lab founded by Nobel laureate Maria Ressa.

It analysed the experiences of 641 women journalists and media workers, activists and human rights defenders from 119 countries. The women were surveyed between 27 August and 13 November 2025.

Researchers found that 27 per cent of women respondents were targeted with unsolicited sexual advances via direct message, receiving unwanted intimate images, “cyberflashing”, sexual innuendos or non-consensual sexting.

A further 12 per cent had their personal images, including those of an intimate nature, shared without their consent, while 6 per cent had been subjected to deepfakes or manipulated images and videos.

The impacts included an alarming rate of mental health diagnoses and self-censorship. Nearly one-quarter, or 24 per cent, of respondents had experienced anxiety and/or depression linked to online violence, while 13 per cent reported being diagnosed with post-traumatic stress disorder, or PTSD.

The findings also pointed to widespread self-censorship, with 41 per cent of respondents saying they self-censored on social media to avoid being abused, and 19 per cent doing so at work.

The study found that while 25 per cent of respondents had reported incidents of online violence to the police and 15 per cent had taken legal action, justice still eluded them. Some 24 per cent of the women who had reported online violence felt victim-blamed by the police, having been asked questions such as “What did you do to provoke the violence?” The same proportion said the police made them feel responsible for shielding themselves from further violence.

Julie Posetti, professor of journalism and chair of the Centre for Journalism and Democracy at City St George’s, is the project’s principal researcher and the report’s lead author.

She said: “AI-assisted ‘virtual rape’ is now at the fingertips of perpetrators. This phenomenon accelerates the harm from online violence inflicted on women in public life.”

“This violence serves to fuel the reversal of women’s hard-won rights in a climate of rising authoritarianism, democratic backsliding and networked misogyny.”

“The rollback of women’s rights is enabled and exacerbated by technologies which, by design, amplify misogynistic hate speech for profit.”

Co-author Lea Hellmueller, associate professor of journalism and associate dean for research and innovation at City St George’s, added: “The chilling effect of online violence is pushing women out of public life.”

“Law enforcement is outsourcing the responsibility for protection to the survivors by telling women to remove themselves from social media, to avoid speaking publicly about controversial issues, to move into less visible roles at work, or to take leave from their respective careers.”

“This shows that avoidance techniques, self-censorship or quitting, are still significantly more likely to be used by women rather than resistance techniques such as reporting online attacks to the police.”

Pauline Renaud, lecturer in journalism at City St George’s and fellow co-author of the study, said: “Going to the police or taking legal action do not necessarily lead to justice for survivors.”

“We need more effective education and training of law enforcement and judicial actors to support action in cases of technology-facilitated violence against women and girls.”

“This needs to be matched by political will to effectively regulate Big Tech companies that use their outsized financial and political power to undermine progress in this area.”

Continue Reading

Fertility

GLP-1 drugs do not increase pregnancy risks, study finds

Published

on

GLP-1 drugs taken before conception were not linked to higher pregnancy risks in new research, which suggested they may even offer some protection.

Women of reproductive age are increasingly prescribed GLP-1 drugs for weight-management support, but the risks and benefits of using them before pregnancy remain poorly understood.

The findings support continuing the use of GLP-1 medicines in women with metabolic risk factors who are considering pregnancy, said Cara Dolin, a maternal-fetal medicine specialist and co-author of the research, which was presented at the Society of Maternal-Fetal Medicine pregnancy meeting in February 2026.

“While there’s more research to be done, this data provides some reassurance that it is not harmful to be taking a GLP-1 if you’re planning a pregnancy, and that having done so may in fact benefit you by optimising your preconception metabolic health.”

The researchers examined electronic medical records for patients with a pre-pregnancy BMI of more than 30 who delivered at more than 20 weeks’ gestation. The data were reviewed for two studies: one assessed the link between pre-pregnancy GLP-1 use and the risk of gestational diabetes, while the second looked at the risk of severe maternal morbidity in patients with obesity.

Women with obesity, diabetes, cardiovascular disease and other cardiometabolic disorders have a higher risk of pregnancy complications including preeclampsia, gestational diabetes, stillbirth, caesarean section and other outcomes. While GLP-1 medicines can help manage these conditions, they are contraindicated during pregnancy, and women are typically advised to stop the medication two months before trying to conceive.

However, stopping the drugs can often lead to rebound weight gain or worsening metabolic health. A 2025 study suggested this rebound worsened some pregnancy outcomes, but the risks and benefits are still poorly understood, Dolin said.

“There is a lot we just don’t know, which is why we wanted to look at our experience here with our Cleveland Clinic patients and see whether taking GLP-1 drugs before pregnancy was causing harm or if it was beneficial and helping patients have healthier pregnancies.”

Researchers analysed data for more than 8,000 women who had obesity but did not have diabetes before they became pregnant. They compared outcomes for 208 women who had been prescribed GLP-1 receptor agonists before pregnancy with those who had not been prescribed the medication.

Women in the GLP-1 group had more risk factors heading into pregnancy. They tended to be older and have a higher body mass index, higher rates of bariatric surgery and chronic high blood pressure, and present earlier for prenatal care.

However, outcomes for the two groups were similar. Researchers found that the GLP-1 group did not have higher rates of gestational diabetes, severe maternal morbidity or other adverse maternal outcomes, suggesting that the medication may have helped mitigate elevated risk factors.

“I think this is a really important signal, and it may reflect that these patients were able to optimise their metabolic health prior to conception.”

“It shows there’s potential to use these drugs in a more targeted way with patients who are planning a pregnancy and have these different comorbidities and obesity.”

While the findings suggest that using GLP-1 drugs before pregnancy may be beneficial in women with metabolic risk factors, having a plan to stop the medicines before conception is essential, Dolin noted. In some cases, patients may be moved to an alternative medication that is safe for pregnancy and can be used to help manage their metabolic health during pregnancy.

Providers with patients who are taking GLP-1 medicines and planning a pregnancy should consider referral to a maternal-fetal medicine specialist for pre-pregnancy counselling.

“We can have a nuanced conversation with the patient about taking the medication, what the benefits are, what the potential risks are, and help them formulate a plan to transition off the medication once they’re ready to start trying to conceive,” she said.

Continue Reading

Cancer

New scan could speed up endometriosis diagnosis

Published

on

Obesity may be a key driver of rising rates of 11 cancers in adults under 50, a study has found.

The 11 cancers were thyroid, multiple myeloma, liver, kidney, gallbladder, colorectal, pancreatic, endometrial, oral, breast and ovarian cancers.

All except oral cancer are known to be linked to excess weight, with researchers saying raised insulin levels and inflammation may play a part.

The findings come from researchers at the Institute of Cancer Research, London and Imperial College London, who analysed national cancer registry data for England from 2001 to 2019.

In England, around 31,000 cancers were diagnosed in people aged 20 to 49 in 2023, equal to roughly one in every 1,000 people. This compares with 244,000 cases in the 50 to 79 age group, where the rate is around one in 100.

Concerns have been growing in recent years over rising rates of cancers such as bowel and ovarian in younger adults.

Among the younger group, breast cancer was the most common, with 8,500 cases, followed by bowel cancer at 3,000 and melanoma skin cancer with 2,800 diagnoses.

For nine of the 11 cancers identified, rates are rising in younger adults but also increasing in older adults, who are much more likely to develop the disease. Bowel and ovarian cancer were the exceptions, rising only in younger age groups.

The researchers found that bowel cancer rates in younger women linked to BMI rose faster, from 0.9 to 1.6 per 100,000 people, than those not linked to BMI, which rose from 6.4 to 9.6 per 100,000 people. Similar patterns were recorded for men.

However, the authors noted that the overall number of cases of BMI-linked bowel cancer in younger women remained lower than those not linked to BMI, suggesting other factors must be contributing to the increase.

Several suspected contributors, including ultra-processed foods, antibiotic use and air pollution, have been proposed in recent years. However, many of these factors have also shown stable or declining trends in the UK, the team said.

Despite the rise in several cancer rates among younger adults over the past two decades, most established risk factors, including smoking, alcohol consumption, red or processed meat intake, low fibre diets and lack of exercise, remained stable or even declined in the period leading up to diagnosis.

This suggests these traditional risk factors are unlikely to account for much of the increase in cancer cases.

By contrast, overweight and obesity, which have increased steadily since 1995, could be key factors in the rise in cases. The team suggested that between 2001 and 2019, around 20 per cent of the increase in bowel cancer was explained by increases in BMI over that period.

However, the researchers said rises in BMI alone are not enough to explain the overall increase in cancer among younger adults in England and that there are likely to be other causes.

Data also suggest around 15 per cent of bowel cancer in younger people could be linked to being overweight or obese, with around 40 to 50 per cent in total linked to the combined effect of known risk factors such as obesity, lack of exercise, alcohol and smoking.

Montse García-Closas, professor at the ICR, said more research was needed, but “we cannot wait to act”.

She told a media briefing: “Our main conclusion is that although BMI is our best clue, much of the increase still remains unexplained, and we’ve done some additional analysis that show that most likely what’s missing is not just a single cause unexplained, but it’s likely a combination of multiple factors that act together.”

Amy Berrington, professor at the ICR, said: “Although rates have been increasing, cancer in young people is still a rare disease.”

Marc Gunter, professor at Imperial, said obesity was a known risk factor for around 19 different cancers.

He added: “For some of these cancers, including colorectal (bowel) cancer, we think this could be partly caused by higher levels of hormones such as insulin, which is often elevated in people with obesity, as well as inflammation.

“We know people with obesity have higher levels of insulin, and insulin is a growth factor and has been linked to cancer.

“In a recent study, we actually found that insulin in particular might be playing a role in early onset colorectal (bowel) cancer, and this is actually an area of very active research at the moment.”

The researchers called for large, long-term studies to identify all the biological and environmental factors that could explain rising cancer rates in young adults.

García-Closas added: “Tackling obesity across all ages, particularly in children and young people, through stronger public health policies and wider access to effective interventions, could slow the rise in cancer and prevent many cancers and must become a national priority.”

Michelle Mitchell, Cancer Research UK’s chief executive, said: “Globally, and in the UK, we’re seeing a small increase in cancer rates in adults under 50.

“The picture is complex and we need more research to understand what’s driving the trend, but this study helps to fill in some gaps.

“Overweight and obesity doesn’t explain the rise in full though. Improvements in detection are likely to also be playing a part, meaning that more people are being diagnosed at a younger age.

“Preventing cancer cases must be a priority for the UK government. Smoking remains a leading cause of cancer in adults under 50, which is why the Tobacco and Vapes Bill receiving royal assent this week is such a historic moment.

“Measures to restrict the advertising and promotion of junk food, introducing mandatory reporting and targets on healthy food sales, and making nutritious food more accessible to everyone would all help people keep a healthy weight.”

Continue Reading

Trending

Copyright © 2025 Aspect Health Media Ltd. All Rights Reserved.